Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 10/2023

03.10.2023 | Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials

verfasst von: Oluwabunmi Ogungbe, Jelani K. Grant, Adeoluwa Segilola Ayoola, Eyram Bansah, Hailey N. Miller, Timothy B. Plante, Payam Sheikhattari, Yvonne Commodore-Mensah, Ruth-Alma N. Turkson-Ocran, Stephen P. Juraschek, Seth S. Martin, Michael Lin, Cheryl R. Himmelfarb, Erin D. Michos

Erschienen in: Current Cardiology Reports | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We review under-representation of key demographic groups in cardiovascular clinical trials, focusing on lipid-lowering trials. We outline multilevel strategies to recruit and retain diverse populations in cardiovascular trials.

Recent Findings

Barriers to participation in trials occur at the study, participant, health system, sponsor, and policy level, requiring a multilevel approach to effectively increase participation of under-represented groups in research. Increasing the representation of marginalized and under-represented groups in leadership positions in clinical trials can ensure that their perspectives and experiences are considered. Trial design should prioritize patient- and community-indicated needs.

Summary

Women and individuals from racially/ethnically diverse populations remain under-represented in lipid-lowering and other cardiovascular clinical trials relative to their disease burden in the population. This limits the generalizability of trial results to the broader population in clinical practice. Collaboration between community stakeholders, researchers, and community members can facilitate shared learning about trials and build trust.
Literatur
1.
Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am. 2022;11.
2.
Wu Y, Prasanna A, Miller HN, et al. Female recruitment into cardiovascular disease trials. Am J Cardiol. 2023;198:88–91.PubMedCrossRef
3.
• Michos ED, Reddy TK, Gulati M, et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: an ASPC practice statement. Am J Prev Cardiol. 2021;8:100250. Useful practice statement from the American Society for Preventive Cardiology about the challenges and potential solutations for improving diversity in clinical trial enrollment.
4.
5.
National Academies of Sciences E, and Medicine, Policy and Global Affairs, Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Why Diverse Representation in Clinical Research Matters and the Current State of Representation within the Clinical Research Ecosystem. Washington (DC). 2022.
6.
Schwartz AL, Alsan M, Morris AA, Halpern SD. Why diverse clinical trial participation matters. N Engl J Med. 2023;388:1252–4.PubMedCrossRef
7.
Zweifler RM, McClure LA, Howard VJ, et al. Racial and geographic differences in prevalence, awareness, treatment and control of dyslipidemia: the reasons for geographic and racial differences in stroke (REGARDS) study. Neuroepidemiology. 2011;37:39–44.PubMedPubMedCentralCrossRef
8.
Dresser R. Wanted Single, White male for medical research. Hastings Cent Rep. 1992;22:24–9.PubMedCrossRef
9.
Liu KA, Mager NA. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract (Granada). 2016;14:708.PubMedCrossRef
10.
Aeschbacher-Germann M, Kaiser N, Speierer A, et al. Lipid-lowering trials are not representative of patients managed in clinical practice: a systematic review and meta-analysis of exclusion criteria. J Am Heart Assoc. 2023;12: e026551.PubMedCrossRef
11.
• Khan SU, Khan MZ, Raghu Subramanian C, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. JAMA Netw Open. 2020;3:e205202. This meta-analysis of lipid lowering trials through 2018 showed that women only consisted of 29% of trial participants and were underrepresented relative to their disease burden in the population.
12.
Khan MS, Shahid I, Siddiqi TJ, et al. Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration approval of novel cardiometabolic drugs. J Am Heart Assoc. 2020;9:e015594.PubMedPubMedCentralCrossRef
13.
Khan SU, Raghu Subramanian C, Khan MZ, et al. Association of women authors with women enrollment in clinical trials of atrial fibrillation. Journal of the American Heart Association, 2022;e024233.
14.
Khan SU, Michos ED. Women in stroke trials-a tale of perpetual inequity in cardiovascular research. JAMA Neurol. 2021;78:654–6.PubMedCrossRef
15.
Whitelaw S, Sullivan K, Eliya Y, et al. Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review. Eur J Heart Fail. 2021;23:15–24.PubMedCrossRef
16.
Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved. 2010;21:879–97.PubMedPubMedCentralCrossRef
17.
Ding EL, Powe NR, Manson JE, Sherber NS, Braunstein JB. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med. 2007;167:905–12.PubMedCrossRef
18.
Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes. 2010;3:135–42.PubMedCrossRef
19.
Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25(563–77):vii.PubMed
20.
Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(Suppl 1):S105–12.PubMedPubMedCentralCrossRef
21.
Brewster RCL, Steinberg JR, Magnani CJ, et al. Race and ethnicity reporting and representation in pediatric clinical trials. Pediatrics. 2023;151.
22.
23.
Boehmer U. Twenty years of public health research: inclusion of lesbian, gay, bisexual, and transgender populations. Am J Public Health. 2002;92:1125–30.PubMedPubMedCentralCrossRef
24.
Caceres BA, Streed CG, Corliss HL, et al. Assessing and addressing cardiovascular health in LGBTQ adults: a scientific statement from the American Heart Association. Circulation. 2020;142:e321–32.PubMedPubMedCentralCrossRef
25.
United States Census Bureau. U.S. Census Bureau. QuickFacts: United States, 2016. 2023.
26.
Frank AT, Zhao B, Jose PO, Azar KM, Fortmann SP, Palaniappan LP. Racial/ethnic differences in dyslipidemia patterns. Circulation. 2014;129:570–9.PubMedCrossRef
27.
Rodriguez F, Hastings KG, Boothroyd DB, et al. Disaggregation of cause-specific cardiovascular disease mortality among Hispanic subgroups. JAMA Cardiol. 2017;2:240–7.PubMedPubMedCentralCrossRef
28.
Mannoh I, Hussien M, Commodore-Mensah Y, Michos ED. Impact of social determinants of health on cardiovascular disease prevention. Curr Opin Cardiol. 2021;36:572–9.PubMedCrossRef
29.
Konindala N, PhyoAung P, Park K. Socioeconomic disparities in dyslipidemia and associated complications: from the latest national database. J Clin Lipidol. 2022;16:e61.CrossRef
30.
Shahu A, Herrin J, Dhruva SS, et al. Disparities in socioeconomic context and association with blood pressure control and cardiovascular outcomes in ALLHAT. J Am Heart Assoc. 2019;8:e012277.PubMedPubMedCentralCrossRef
31.
Lofters AK, Guilcher SJ, Webster L, Glazier RH, Jaglal SB, Bayoumi AM. Cholesterol testing among men and women with disability: the role of morbidity. Clin Epidemiol. 2016;8:313–21.PubMedPubMedCentralCrossRef
32.
Osibogun O, Ogunmoroti O, Mathews L, Okunrintemi V, Tibuakuu M, Michos ED. Greater acculturation is associated with poorer cardiovascular health in the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2021;10:e019828.PubMedPubMedCentralCrossRef
33.
George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health. 2014;104:e16-31.PubMedPubMedCentralCrossRef
34.
Johnson VA, Edwards KA, Sherman SL, et al. Decisions to participate in fragile X and other genomics-related research: Native American and African American voices. J Cult Divers. 2009;16:127–35.PubMed
35.
Association of American Medical Colleges. The diversity research forum: the importance and benefits of diverse faculty in academic medicine: implications for recruitment, retention, and promotion. Washington, DC. 2009.
36.
37.
38.
Burns KEA, Straus SE, Liu K, Rizvi L, Guyatt G. Gender differences in grant and personnel award funding rates at the Canadian Institutes of Health Research based on research content area: A retrospective analysis. PLoS Med. 2019;16:e1002935.PubMedPubMedCentralCrossRef
39.
Shahid I, Khan MS, Siddiqi TJ, et al. Trends in National Institutes of Health R01 Funding of Principal Investigators in Cardiology by Gender. J Am Coll Cardiol. 2022;79:1544–6.PubMedPubMedCentralCrossRef
40.
Striving for diversity in research studies. N Engl J Med. 2021;385:1429–30.CrossRef
41.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–621.PubMedCrossRef
42.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046–81.PubMed
43.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.PubMedCrossRef
44.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. 1991.
45.
Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). 1994.
46.
Shepherd J, Cobbe Sm Fau - Ford I, Ford I Fau - Isles CG, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. 1995.
47.
Sacks FM, Pfeffer Ma Fau - Moye LA, Moye La Fau - Rouleau JL et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. 1996.
48.
Investigators TPCABGT. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. 1997.
49.
Lewis SJ, Moye La Fau - Sacks FM, Sacks Fm Fau-Johnstone DE, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. 1998.
50.
Downs JR, Clearfield M Fau-Weis S, Weis S Fau-Whitney E, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. 1998.
51.
Group L-TIwPiIDLS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. 1998.
52.
Athyros VG, Papageorgiou Aa Fau-Mercouris BR, Mercouris Br Fau - Athyrou VV, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. 2002.
53.
Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 2002.
54.
Shepherd J, Blauw Gj Fau - Murphy MB, Murphy Mb Fau - Bollen ELEM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. 2002.
55.
Serruys PW, de Feyter P Fau-Macaya C, Macaya C Fau-Kokott N, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. 2002.
56.
Group TAOaCftACR. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). 2002.
57.
Sever PS, Dahlöf B Fau-Poulter NR, Poulter Nr Fau-Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial--lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. 2003.
58.
Holdaas H, Fellström B Fau-Jardine AG, Jardine Ag Fau-Holme I, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. 2003.
59.
Colhoun HM, Betteridge Dj Fau-Durrington PN, Durrington Pn Fau-Hitman GA, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. 2004.
60.
Cannon CP, Braunwald E Fau-McCabe CH, McCabe Ch Fau-Rader DJ, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. 2004.
61.
de Lemos JA, Blazing Ma Fau-Wiviott SD, Wiviott Sd Fau-Lewis EF, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. 2004.
62.
Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. 2004.
63.
Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarctionthe IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.PubMedCrossRef
64.
Wanner C, Krane V Fau - März W, März W Fau - Olschewski M, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. 2005.
65.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.PubMedCrossRef
66.
Knopp RH, d'Emden M Fau - Smilde JG, Smilde Jg Fau - Pocock SJ, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). 2006.
67.
Investigators TSPbARiCLS. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine. 2006;355:549–559.
68.
Yokoyama M, Origasa H Fau - Matsuzaki M, Matsuzaki M Fau - Matsuzawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. 2007.
69.
Nakamura H. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin. 2007.
70.
Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.PubMedCrossRef
71.
Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedCrossRef
72.
Tavazzi L Fau - Maggioni AP, Maggioni Ap Fau - Marchioli R, Marchioli R Fau - Barlera S, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. 2008.
73.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef
74.
Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.PubMedCrossRef
75.
Armitage J Fau - Bowman L, Bowman L Fau-Wallendszus K, Wallendszus K Fau-Bulbulia R, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. 2010.
76.
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. The Lancet. 2011;377:2181–92.CrossRef
77.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.PubMedCrossRef
78.
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.PubMedCrossRef
79.
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9.PubMedCrossRef
80.
Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021–31.PubMedCrossRef
81.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.PubMedCrossRef
82.
Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–39.PubMedCrossRef
83.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. 2018.
84.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.PubMedCrossRef
85.
Amarenco P, Kim JS, Labreuche J, et al. Benefit of targeting a LDL (low-density lipoprotein) cholesterol <70 mg/dL during 5 years after ischemic stroke. Stroke. 2020;51:1231–9.PubMedCrossRef
86.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353–64. https://​doi.​org/​10.​1056/​NEJMoa2215024.
87.
Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. 2014;16:810–9.PubMedPubMedCentralCrossRef
88.
• Grant JK, Dangl M, Koester M, et al. Under-reporting and under-representation of non-Hispanic Black subjects in lipid-lowering atherosclerotic cardiovascular disease outcomes trials: a systematic review. Journal of clinical lipidology. 2022;16:608–616. Meta-analysis of lipid lowering trials through 2020 showed that Black participants were substantially underrepresented relative to their disease burden in the population and that results are underreported by race/ethnicity.
89.
Pearson TA, Denke MA, McBride PE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc. 2006;81:1177–85.PubMedCrossRef
90.
Ferdinand KC, Jacobson TA, Koren A, Elassal J, Thompson D, Deedwania P. Alirocumab efficacy and safety by race and ethnicity: analysis from 3 ODYSSEY phase 3 trials. J Clin Lipidol. 2019;13(586–593):e5.
91.
Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies. J Am Heart Assoc. 2021;10:e016839.
92.
Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA: results from the 3146 patients randomized in the United States. Circulation. 2020;141:367–75.PubMedCrossRef
93.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England journal of medicine. 1995;333:1301–7.
94.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.
95.
Heart Protection Study Collaborative G. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (London, England). 2002;360:7–22.
96.
Officers A, Coordinators for the ACRGTA, lipid-lowering treatment to prevent heart attack T. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.
97.
Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (London, England). 2003;361:1149–58.PubMedCrossRef
98.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (London, England). 2002;360:1623–30.PubMedCrossRef
99.
Bodicoat DH, Routen AC, Willis A, et al. Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action. Trials. 2021;22:880.PubMedPubMedCentralCrossRef
100.
• Michos ED, Van Spall HGC. Increasing representation and diversity in cardiovascular clinical trial populations. Nat Rev Cardiol. 2021;18:537–538. Useful perspective in Nature outlining multi-level strategies for improving representations of diverse populations into clinical trials at the participant, investigator, institution, funder, and journal levels.
101.
Clark LT, Watkins L, Pina IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44:148–72.PubMedCrossRef
102.
Cushman M, Shay CM, Howard VJ, et al. Ten-Year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association national survey: a special report from the American Heart Association. Circulation. 2021;143:e239–48.PubMedCrossRef
103.
Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C. Community programs for the prevention of cardiovascular disease: a systematic review. Am J Epidemiol. 2010;172:501–16.PubMedCrossRef
104.
Balcazar HG, de Heer H, Rosenthal L, et al. A promotores de salud intervention to reduce cardiovascular disease risk in a high-risk Hispanic border population, 2005–2008. Prev Chronic Dis. 2010;7:A28.PubMedPubMedCentral
105.
Reza N, Gruen J, Bozkurt B. Representation of women in heart failure clinical trials: barriers to enrollment and strategies to close the gap. Am Heart J Plus. 2022;13.
106.
Durant RW, Legedza AT, Marcantonio ER, Freeman MB, Landon BE. Willingness to participate in clinical trials among African Americans and whites previously exposed to clinical research. J Cult Divers. 2011;18:8–19.PubMedPubMedCentral
107.
Shen MJ, Peterson EB, Costas-Muniz R, et al. The effects of race and racial concordance on patient-physician communication: a systematic review of the literature. J Racial Ethn Health Disparities. 2018;5:117–40.PubMedCrossRef
108.
Saha S, Beach MC. Impact of physician race on patient decision-making and ratings of physicians: a randomized experiment using video vignettes. J Gen Intern Med. 2020;35:1084–91.PubMedPubMedCentralCrossRef
109.
Denby KJ, Szpakowski N, Silver J, Walsh MN, Nissen S, Cho L. Representation of women in cardiovascular clinical trial leadership. JAMA Intern Med. 2020;180:1382–3.PubMedPubMedCentralCrossRef
110.
Shahid I, Khan MS, Sohail A, et al. Evaluation of representation of women as authors in pivotal trials supporting US Food and Drug Administration approval of novel cardiovascular drugs. JAMA Netw Open. 2022;5: e220035.PubMedPubMedCentralCrossRef
111.
Whitelaw S, Thabane L, Mamas MA, et al. Characteristics of heart failure trials associated with under-representation of women as lead authors. J Am Coll Cardiol. 2020;76:1919–30.PubMedPubMedCentralCrossRef
112.
Reza N, Tahhan AS, Mahmud N, et al. Representation of women authors in international heart failure guidelines and contemporary clinical trials. Circ Heart Fail. 2020;13: e006605.PubMedPubMedCentralCrossRef
113.
Taani MH, Zabler B, Fendrich M, Schiffman R. Lessons learned for recruitment and retention of low-income African Americans. Contemp Clin Trials Commun. 2020;17: 100533.PubMedPubMedCentralCrossRef
114.
Ortega RF, Yancy CW, Mehran R, Batchelor W. Overcoming lack of diversity in cardiovascular clinical trials: a new challenge and strategies for success. Circulation. 2019;140:1690–2.PubMedCrossRef
115.
Gadegbeku CA, Stillman PK, Huffman MD, Jackson JS, Kusek JW, Jamerson KA. Factors associated with enrollment of African Americans into a clinical trial: results from the African American study of kidney disease and hypertension. Contemp Clin Trials. 2008;29:837–42.PubMedPubMedCentralCrossRef
116.
Adeyemi OF, Evans AT, Bahk M. HIV-infected adults from minority ethnic groups are willing to participate in research if asked. AIDS Patient Care STDS. 2009;23:859–65.PubMedCrossRef
117.
Rucker-Whitaker C, Flynn KJ, Kravitz G, Eaton C, Calvin JE, Powell LH. Understanding African-American participation in a behavioral intervention: results from focus groups. Contemp Clin Trials. 2006;27:274–86.PubMedCrossRef
118.
Quinn SC, Butler J 3rd, Fryer CS, et al. Attributes of researchers and their strategies to recruit minority populations: results of a national survey. Contemp Clin Trials. 2012;33:1231–7.PubMedPubMedCentralCrossRef
119.
Butler J 3rd, Quinn SC, Fryer CS, Garza MA, Kim KH, Thomas SB. Characterizing researchers by strategies used for retaining minority participants: results of a national survey. Contemp Clin Trials. 2013;36:61–7.PubMedPubMedCentralCrossRef
120.
Niranjan SJ, Durant RW, Wenzel JA, et al. Training needs of clinical and research professionals to optimize minority recruitment and retention in cancer clinical trials. J Cancer Educ. 2019;34:26–34.PubMedPubMedCentralCrossRef
121.
Webb FJ, Khubchandani J, Striley CW, Cottler LB. Black-White differences in willingness to participate and perceptions about health research: results from the population-based healthstreet study. J Immigr Minor Health. 2019;21:299–305.PubMedPubMedCentralCrossRef
122.
Joseph G, Dohan D. Diversity of participants in clinical trials in an academic medical center: the role of the ‘Good Study Patient?’ Cancer. 2009;115:608–15.PubMedCrossRef
123.
Passmore SR, Farrar Edwards D, Sorkness CA, Esmond S, Brasier AR. Training needs of investigators and research team members to improve inclusivity in clinical and translational research participation. J Clin Transl Sci. 2020;5: e57.PubMedPubMedCentralCrossRef
124.
Heller C, Balls-Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials. 2014;39:169–82.PubMedPubMedCentralCrossRef
125.
• Prasanna A, Miller HN, Wu Y, et al. Recruitment of Black adults into cardiovascular disease trials. Journal of the American Heart Association. 2021;10:e021108. This analysis concluded the Black participants were underrepresented in NIH-funded cardiovascular trials and that most trial protocols did not outline specific plans to enroll Black adults, or set a target enrollment for Black participants, or if specified, did not meet those targets.
126.
Cooper LA, Beach MC, Johnson RL, Inui TS. Delving below the surface. Understanding how race and ethnicity influence relationships in health care. J Gen Intern Med. 2006;21 Suppl 1:S21–7.
127.
Commodore-Mensah Y, Turkson-Ocran RA, Nmezi NA, et al. Commentary: engaging African immigrants in research experiences and lessons from the field. Ethn Dis. 2019;29:617–22.PubMedPubMedCentralCrossRef
128.
Han HR, Xu A, Mendez KJW, et al. Exploring community engaged research experiences and preferences: a multi-level qualitative investigation. Res Involv Engagem. 2021;7:19.PubMedPubMedCentralCrossRef
129.
Rubinger L, Gazendam A, Ekhtiari S, et al. Maximizing virtual meetings and conferences: a review of best practices. Int Orthop. 2020;44:1461–6.PubMedCrossRef
130.
LaFave SE, Wallace DJ, Grover R, Clark R, Marks S, Lacanienta C, Evans C, Kalil GZ, Ouyang P, Himmelfarb CR, Abshire M. Building a pipeline of community-engaged researchers: how interdisciplinary translational research training programs can collaborate with their Community Research Advisory Councils. J Clin Transl Sci. 2021;5(1):e156. https://​doi.​org/​10.​1017/​cts.​2021.​818.
131.
Byiringiro S, Lacanienta C, Clark R, Evans C, Stevens S, Reese M, Ouyang P, Terkowitz M, Weston C, Galiatsatos P, Guerrero Vazquez M, Luthardt FW, Dennison Himmelfarb CR. Digital and virtual strategies to advance community stakeholder engagement in research during COVID-19 pandemic. J Clin Transl Sci. 2022;6(1):e121. https://​doi.​org/​10.​1017/​cts.​2022.​457.
132.
Goodman MS, Sanders Thompson VL, Johnson CA, et al. Evaluating community engagement in research: quantitative measure development. J Community Psychol. 2017;45:17–32.PubMedCrossRef
133.
Goodman MS, Ackermann N, Bowen DJ, Panel D, Thompson VS. Reaching consensus on principles of stakeholder engagement in research. Prog Community Health Partnersh. 2020;14:117–27.PubMedCrossRef
134.
Sheikhattari P, Shaffer E, Barsha RAA, et al. Building capacity for community-academia research partnerships by establishing a physical infrastructure for community engagement: Morgan CARES. Int J Environ Res Public Health. 2022;19.
135.
Benizri N, Hallot S, Burns K, Goldfarb M. Patient and family representation in randomized clinical trials published in 3 medical and surgical journals: a systematic review. JAMA Netw Open. 2022;5:e2230858–e2230858.PubMedPubMedCentralCrossRef
136.
Goldfarb MJ, Bechtel C, Capers Q, et al. Engaging families in adult cardiovascular care: a scientific statement from the American Heart Association. J Am Heart Assoc. 2022;11: e025859.PubMedPubMedCentralCrossRef
137.
Greiner KA, Friedman DB, Adams SA, et al. Effective recruitment strategies and community-based participatory research: community networks program centers’ recruitment in cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2014;23:416–23.PubMedPubMedCentralCrossRef
138.
Riesch SK, Ngui EM, Ehlert C, et al. Community outreach and engagement strategies from the Wisconsin Study Center of the National Children’s Study. Public Health Nurs. 2013;30:254–65.PubMedPubMedCentralCrossRef
139.
140.
141.
142.
143.
144.
145.
146.
Niyibizi N, McIntosh S, Hudson BL, Sipocz A, Paku E, Dykes C. CTSA recruitment resources: an inventory of what CTSA hubs are currently offering. J Clin Transl Sci. 2020;4:529–36.PubMedPubMedCentralCrossRef
147.
Peeler A, Miller H, Ogungbe O, Lewis Land C, Martinez L, Guerrero Vazquez M, Carey S, Murli S, Singleton M, Lacanienta C, Gleason K, Ford D, Himmelfarb CR. Centralized registry for COVID-19 research recruitment: Design, development, implementation, and preliminary results. J Clin Transl Sci. 20214;5(1):e152. https://​doi.​org/​10.​1017/​cts.​2021.​819.
148.
149.
Plante TB, Gleason KT, Miller HN, Charleston J, McArthur K, Himmelfarb CD, Lazo M, Ford DE, Miller ER 3rd, Appel LJ, Juraschek SP; STURDY Collaborative Research Group. Recruitment of trial participants through electronic medical record patient portal messaging: A pilot study. Clin Trials. 2020;17(1):30–8. https://​doi.​org/​10.​1177/​1740774519873657​.
150.
151.
152.
Piasecki RJ, Quarles ED, Bahouth MN, Nandi A, Bilheimer A, Carter-Edwards L, Dennison-Himmelfarb CR. Aligning community-engaged research competencies with online training resources across the Clinical and Translational Science Award Consortium. J Clin Transl Sci. 2020;5(1):e45. https://​doi.​org/​10.​1017/​cts.​2020.​538.
153.
Bailey ZD, Krieger N, Agenor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet (London, England). 2017;389:1453–63.PubMedCrossRef
154.
Nicholson LM, Schwirian PM, Groner JA. Recruitment and retention strategies in clinical studies with low-income and minority populations: Progress from 2004–2014. Contemp Clin Trials. 2015;45:34–40.PubMedCrossRef
155.
156.
Jacobs JW, Adkins BD, Bibb LA, Booth GS. Diversity, equity, and inclusion editorial positions among high-impact biomedical journals. Curr Med Res Opin. 2023;39:383–6.PubMedCrossRef
157.
Sacristan JA, Aguaron A, Avendano-Sola C, et al. Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence. 2016;10:631–40.PubMedPubMedCentralCrossRef
158.
Hedges JR, Soliman KFA, Southerland WM, et al. Strengthening and sustaining inter-institutional research collaborations and partnerships. Int J Environ Res Public Health. 2021;18.
Metadaten
Titel
Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials
verfasst von
Oluwabunmi Ogungbe
Jelani K. Grant
Adeoluwa Segilola Ayoola
Eyram Bansah
Hailey N. Miller
Timothy B. Plante
Payam Sheikhattari
Yvonne Commodore-Mensah
Ruth-Alma N. Turkson-Ocran
Stephen P. Juraschek
Seth S. Martin
Michael Lin
Cheryl R. Himmelfarb
Erin D. Michos
Publikationsdatum
03.10.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 10/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01942-2

Weitere Artikel der Ausgabe 10/2023

Current Cardiology Reports 10/2023 Zur Ausgabe

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Improving Hypertension Control in Vulnerable Populations Around the World

Valvular Heart Disease (TL Kiefer, Section Editor)

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

Psychological Aspects of Cardiovascular Diseases (IM Kronish, Section Editor)

Screening for Emotional Distress in Patients with Cardiovascular Disease

Correction

Correction to: Left Atrial Appendage Closure with Watchman vs Amulet Devices: Similarities and Differences

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Arterial Stiffness and its Impact on Cardiovascular Health

Heart Failure (HJ Eisen, Section Editor)

The Effect of EECP on Ischemic Heart Failure: a Systematic Review

Neu im Fachgebiet Kardiologie

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise